News | July 30, 2025
Ajanta Pharma reports Q1 FY26 consolidated PAT at Rs. 255.34 Cr
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
Ajanta Pharma has reported total income of Rs. 1,328.98 crores during the period ended June 30, 2025
The company would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal
Novartis India has reported total income of Rs. 98.16 crores during the period ended June 30, 2025
Torrent Pharmaceuticals has reported total income of Rs. 3,141 crores during the period ended June 30, 2025
Piramal Pharma has reported total income of Rs. 1,992.11 crores during the period ended June 30, 2025
This achievement is part of the population-based initiative for screening, prevention, and management of Non-Communicable Diseases
Sigachi Industries has reported total income of Rs. 132.18 crores during the period ended June 30, 2025
Carbamazepine Extended-Release Tablets are indicated for use as an anticonvulsant drug
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
Subscribe To Our Newsletter & Stay Updated
